CIK 0001953926 · <br>Emerging growth company
Zenas BioPharma, Inc.
Sign in to watch- Ticker
- ZBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-271-2954
- Business address
- 852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
- Former names
- Zenas BioPharma (Cayman) Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-20 | MOULDER LEON O JR Chief Executive Officer | Purchase | +2,633 | $18.97 | $50K | 1,672,039 |
| 2024-09-19 | MOULDER LEON O JR Chief Executive Officer | Purchase | +5,000 | $17.89 | $89K | 1,667,039 |
| 2024-09-18 | MOULDER LEON O JR Chief Executive Officer | Purchase | +10,000 | $17.91 | $179K | 1,662,039 |
| 2024-09-16 | Enavate Sciences GP, LLC 10% owner | Conversion | +2,879,006 | 2,879,006 | ||
| 2024-09-16 | Enavate Sciences GP, LLC 10% owner | Purchase | +882,353 | $17.00 | $15.0M | 3,761,359 |
| 2024-09-16 | Enavate Sciences GP, LLC 10% owner | Conversion · Series B Preferred Stock | −10,474,889 | 0 | ||
| 2024-09-16 | Enavate Sciences GP, LLC 10% owner | Conversion · Series C Preferred Stock | −14,523,821 | 0 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +180,635 | 180,635 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +420,271 | 600,906 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +200,718 | 801,624 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −1,568,480 | 0 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −3,649,263 | 0 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −1,742,858 | 0 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +41,130 | 329,045 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +252,890 | 581,935 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +709,794 | 1,291,729 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion | +301,077 | 1,592,806 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Purchase | +300,000 | $17.00 | $5.1M | 1,892,806 |
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion · Series Seed Convertible Preferred Stock | −357,143 | 0 | ||
| 2024-09-16 | Fairmount Funds Management LLC Director | Conversion · Series A Convertible Preferred Stock | −2,195,871 | 0 |
Page 4 of 8 · 145 trades